Clinical Trial Update: SUV on 68Ga-DOTATATE PET/CT and Ki-67 Index in Neuro-Endocrine Tumors [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating SUV on 68Ga-DOTATATE PET/CT and Ki-67 index in neuroendocrine tumors has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroendocrine Tumor

Drugs mentioned

• 68Ga-DOTATATE (Gallium-68 DOTATATE)

Snippet

Sponsor: Jewish General Hospital | Conditions: Neuroendocrine Tumors | Phase 3 | Status: COMPLETED